Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- WHO classification of tumours of haematopoietic and lymphoid tissues.4th edition. IARC, Lyon2017
- Genomic complexity of multiple myeloma and its clinical implications.Nat Rev Clin Oncol. 2017; 14: 100-113
- Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.Skeletal Radiol. 2022; 51: 17-30
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol. 2016; 17: e328-e346
- Recent advances in cytogenetic characterization of multiple myeloma.Int J Lab Hematol. 2019; 41: 5-14
- Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.Leukemia. 2003; 17: 427-436
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: The IFM experience.Blood. 2015; 125: 2095-2100
- Revised international staging system for multiple myeloma: A report from international myeloma working group.J Clin Oncol. 2015; 33: 2863-2869
- Characteristics of exceptional responders to lenalidomide- based therapy in multiple myeloma.Blood Cancer J. 2015; : e363
- Reconstructing the evolutionary history of multiple myeloma.Best Pract Res Clin Haematol. 2020; 33: 101145
- Genomic landscape and chronological reconstruction of driver events in multiple myeloma.Nat Commun. 2019; 10: 1-12
- Genome instability in multiple myeloma.Leukemia. 2020; 34: 2887-2897
- Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.Blood. 2015; 125: 831-840
- The multiple myelomas - Current concepts in cytogenetic classification and therapy.Nat Rev Clin Oncol. 2018; 15: 409-421
- Genomic analysis of high-risk smoldering multiple myeloma.Haematologica. 2012; 97: 1439-1443
- Genomic abnormalities in monoclonal gammopathy of undetermined significance.Blood. 2002; 100: 1417-1424
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.Leukemia. 2013; 27: 1738-1744
- Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis.Blood Cancer J. 2020; 10: 1-5
- Effect of t (11;14) Abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry.Clin Lymphoma, Myeloma Leuk. 2022; 22: 149-157
- Evolution and structure of clinically relevant gene fusions in multiple myeloma.Nat Commun. 2020; 11: 1-12
- The molecular classification of multiple myeloma.Blood. 2006; 108: 2020-2028
- Toward personalized treatment in multiple myeloma based on molecular characteristics.Blood. 2019; 133: 660-675
- MYC dysregulation in the progression of multiple myeloma.Leukemia. 2020; 34: 322-326
Walker B.A., Wardell C.P., Murison A., et al., APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma, Nat Commun, 6, 2015, 1-15.
- Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.Blood Cancer J. 2014; 4: e191-e197
- The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma.Clin Cancer Res. 2021; 27: 5430-5439
- A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.Blood. 2010; 116: 56-65
- Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13.Br J Haematol. 2000; 111: 1116-1117
- Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome.Blood. 2007; 109: 3489-3495
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.Leukemia. 2019; 33: 159-170
- Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.J Clin Oncol. 2020; 38: 2380-2389
- Targeting the MTF2–MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy.Cancer Discov. 2018; 8: 1376-1389
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.Blood. 2018; 132: 587-597
Bolli N., Avet-Loiseau H., Wedge D.C., et al., Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat Commun, 5, 2014, 1–16.
- Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy.Cancer Cell. 2014; 25: 91-101
- Initial genome sequencing and analysis of multiple myeloma.Nature. 2011; 471: 467-472
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.Lancet Oncol. 2021; 22: E105-E118
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood. 2018; 132: 2456-2464
- Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.Haematologica. 2005; 90: 1365-1372
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia. 2017; 31: 2094-2103
- Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials.J Clin Oncol. 2017; 35: 2900-2910
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Blood. 2008; 112: 4017-4023
- Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.J Clin Oncol. 2011; 29: 1627-1633
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood. 2014; 123: 3073-3079
- Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.Leukemia. 2014; 28: 391-397
- Minimal residual disease detection by next-generation sequencing in multiple myeloma: a comparison with real-time quantitative PCR.Front Oncol. 2021; 10: 1-5
- Measurable residual disease in multiple myeloma: ready for clinical practice?.J Hematol Oncol. 2020; 13: 1-8
- Circulating tumour DNA for detecting minimal residual disease in multiple myeloma.Semin Hematol. 2018; 55: 38-40
- Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Nat Commun. 2018; 9: 1-11
- Cell-free DNA for the detection of emerging treatment failure in relapsed/refractory multiple myeloma.Leuk. 2022; 36 (2021 364): 1078-1087
- Clinical significance of circulating cell-free DNA detection in multiple myeloma: a meta-analysis.Front Oncol. 2022; 12: 1-8
- Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.Blood Adv. 2018; 2: 2811-2813
- Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.Eur J Haematol. 2020; 104: 190-197
- Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study.J Mol Diagnostics. 2018; 20: 859-870
- Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.Leukemia. 2020; 34: 3007-3018
- Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).Blood Cancer J. 2018; 8https://doi.org/10.1038/s41408-018-0153-9
- Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.Leukemia. 2020; 34: 589-603
- Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.Blood Adv. 2022; 6: 3234-3239
- Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow.Clin Chem. 2021; 67: 1689-1698
- Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.Blood Cancer J. 2021; 11: 2-5
Article info
Publication history
Published online: March 10, 2023
Publication stage
In Press Corrected ProofFootnotes
The authors have no relevant conflicts of interest to disclose.
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
